Summary We have investigated the possibility that structural alterations of the 'nuclear' oncogene family (c-myc, N-myc, L-myc, fos, myb and p53) leading to aberrant expression might, as in several other tumour types, play a role in the multi-stage development of tumorigenesis in the human thyroid follicular cell. Direct analysis of expression by slot and Northern blot RNA hybridisation showed that normal thyroid expresses surprisingly high levels of fos, and to a lesser extent c-myc. c-myc expression was markedly increased in all tumours, both benign and malignant, but no increase was seen in any other nuclear oncogene. fis expression was reduced specifically in one type of malignant tumour -follicular carcinoma -in inverse correlation with differentiation. Southern blot analysis showed no evidence of rearrangement or amplification of c-myc, or of any other 'nuclear' oncogene in any thyroid tumour. We conclude that there is no evidence that a primary abnormality of these genes plays a role in thyroid follicular cell tumorigenesis and suggest that the observed changes in expression can be adequately explained as secondary consequences of the tumour phenotype.
The so-called 'nuclear' oncogenes c-myc, N-myc, L-myc, myb, fos, and p53 code for a group of related oncoproteins which share the properties of nuclear localisation and binding to nuclear matrix/DNA, several members of which have been implicated in control of gene transcription and cell proliferation (for review see Alitalo et al., 1987) . In vitro studies have shown that experimentally induced overexpression of most members of the group can synergise with activated (mutated) ras oncogenes to bring about malignant transformation of primary (mainly mesenchymal) cells (Weinberg, 1985) . In vivo, in both human and experimental tumours, deregulated expression of these genes has been found as one of several presumed co-operating genetic lesions -for example c-myc with N-ras in promyelocytic leukaemia (Land et al., 1983) and with K-ras in radiation-induced rat skin tumours (Sawey et al., 1987) . In addition, overexpression, particularly of the myc family, is a consistent feature of progression to more advanced malignancy in several tumour types, notably neuroblastoma (Schwab et al., 1984) and small cell lung cancer (Nau et al., 1986) .
In all cases where overexpression occurs through a primary defect in the gene locus, two major mechanisms have been observed (Alitalo et al., 1987) : (a) rearrangements due to chromosome translocation which affect the function of regulatory elements of the gene; and (b) amplification of the intact locus, leading to an increased number of otherwise normal copies of the gene. In thyroid follicular cell tumours we have recently shown that activation of the ras family of oncogenes is frequently found, not only in follicular carcinomas but also in adenomas (Lemoine et al., 1988 a, b) . Since ras activation therefore appears to be an early (premalignant) event we have begun investigating the nature of the additional genetic changes which must determine progression to malignancy and in some cases to anaplastic cancer. As a first step we have looked for the presence of abnormalities of structure (rearrangements or amplification) and of expression of members of the nuclear oncogene group in these tumours.
Materials and methods

Tumours
We analysed the following thyroid follicular cell tumours (classified (Maniatis et al., 1982) and blotted on to nylon membranes (Hybond, Amersham) . Membranes were hybridised to 32P-labelled probes prepared by the random primer method (Feinberg & Vogelstein, 1983 ) and washed to high stringency (0.1 x SSC, 65°C). To control for variation in amount of DNA loaded, each membrane was rehybridised with a second probe, pHPT3 1 (Brennand et al., 1983) , specific for the 'housekeeping' gene hypoxanthine phosphoribosyltransferase (HPRT) to provide an internal standard in assessing oncogene amplification. The intensity of autoradiographic bands was quantified by scanning densitometry.
Probes and restriction enzymes
The restriction enzymes used to digest the genomic DNA and the probes used for hybridisation were chosen so as to cover the coding sequence of each gene and as much as possible of the 5' and 3' regions in order to maximise the chances of detecting rearrangements. The enzymes and probes used for each gene and the regions of each locus effectively probed are detailed in Table I guanidinium thiocyanate followed by centrifugation through caesium chloride (Chirgwin et al., 1979) .
Slot blot analysis RNA was denatured (2.2 M formaldehyde, 65'C, 10 min) and applied to nitrocellulose membranes in a vacuum slot blot apparatus (Millipore). For each case, three 4-fold dilutions, beginning with 41g total RNA, were analysed. In addition, to control for contaminating DNA, a fourth slot was included containing 4 ;g RNA pre-treated with 0.3 M NaOH (65'C, 1 h). Prehybridisation and hybridisation were carried out in 50% formamide at 42'C as described (Maniatis et al., 1982) . Blots were washed to high stringency (0.1 x SSC, 65°C).
Northern blot analysis
Ten to 20 fig denatured total RNA was electrophoresed through a 1% agarose/formaldehyde gel in 2.2 M formaldehyde in 0.04 M MOPS buffer (Maniatis et al., 1982) and blotted on to nitrocellulose as described (Thomas, 1980) . Hybridisation and washing were as for slot blots.
Results
RNA analysis
Total RNA from tumour and normal thyroid samples was first analysed by slot blot hybridisation. The level of expression of each oncogene was compared to that of the housekeeping gene HPRT, the expression of which can be assumed to be independent of proliferative rate or neoplastic phenotype, to control for unavoidable variations in amount of RNA loaded between samples. Oncogene expression was also compared with that of thyroglobulin (TG), which is a highly expressed differentiation marker of normal thyroid. Finally, all samples were hybridised in parallel with slots containing 4 fig of denatured normal human DNA to control for differences in specific activity between the various probes.
Simple inspection of the autoradiographs (for a representative subset of samples see Figure 1) The values of S obtained for c-myc and fos in this way were expressed as a proportion ofthe corresponding value for HPRT so as to correct for variations in total RNA available for hybridisation. The results (Table II) confirm the general pattern suggested by Figure 1 . In normal thyroid, there is a high level of fos transcripts, 4.6 ± 1.7 fold (mean ± s.e.) higher than HPRT, and a lower abundance ofc-myc, 0.09 ± 0.02 fold HPRT. While there is overlap between the groups, benign tumours (adenomas) showed a very significantly higher abundance of c-myc than in normal thyroid (c-myc/HPRT ratio 0.55 ± 0.17 compared to 0.09 ± 0.02; P<0.01). Similar high levels were found in the differentiated malignant tumour groups (follicular and papillary carcinomas); the single case of anaplastic cancer for which RNA was available gave an even higher c-myc signal but the statistical significance of this cannot be assessed until further cases are analysed. There was no statistically significant change in fos expression except in the follicular carcinomas which showed a marked decrease in fos/HPRT ratio from 4.6 ± 1.7 in normal to 0.19 ± 0.07 (P<0.001).
Selected cases, including the follicular carcinomas, were further analysed by Northern blotting. Transcripts of the expected size were found for HPRT,fos and c-myc, the intensity of which correlated well with the signals obtained in the corresponding slot blots. In particular, Northern analysis confirmed that the loss offos hybridisation signal in FCl was not the result of RNA degradation, and that the expected size transcript detected in normal and other tumour samples was absent in this tumour (Figure 2 ).
Genomic analysis
A representative Southern blot, of the fos locus, is shown in Figure 3 . It can be seen that although the absolute intensity varies from case to case due to inevitable variations in amount of DNA loaded, the ratio of fos to HPRT signals is not increased in tumour DNA compared to controls. There is therefore no increase in copy number of the fos gene in these tumours.
Comparison of the migration of the fos-specific restriction fragment with that of the size markers (HindIII digest of phage A ) shows the expected size of 9.0 kbp in both tumours and controls. There is therefore no evidence of rearrangement or deletion of the fos locus in these tumours.
Comparable Southern blot analysis of normal and thyroid tumour DNAs using probes for the five other nuclear oncogenes (c-myc, N-myc, L-myc, myb and p53) also showed restriction fragments of normal size and abundance in all tumours in our series.
Discussion
Our data show that, in agreement with two previous studies (Aasland et al., 1988; Terrier et al., 1988) , normal adult thyroid contains c-myc transcripts readily detectable in total cellular RNA (a perhaps surprising result in view of its extremely low level of mitotic activity; Wright & Alison, 1984) . In contrast to previous reports, however, we have observed a marked (6-fold) increase in expression of c-myc in benign as well as malignant thyroid tumours. Aasland et al. (1988) found elevation only in an anaplastic tumour (although follicular carcinomas were not included) and Terrier et al. (1988) found increased myc to be confined to the malignant tumours, and indeed to correlate with poor prognosis within this group. The basis for these differences is not clear, although some aspects of the methodology of the latter study are difficult to interpret. The reference level to which expression was compared, for example, is not clear, and both normal and tumour groups apparently contained samples showing 'raised' levels. The discordance is important since our data, unlike those of Terrier et al., do not support a role for increased c-myc expression in malignant progression. Cell culture observations of the role of myc in thyrocytes, in both primary and established cells have shown that the thyroid mitogens, TSH and EGF, both induce increases in c-myc transcript abundance (Dere et al., 1985; Reuse et al., 1986; Colletta et al., 1986) analogous to that seen in fibroblasts and lymphocytes following mitogen stimulation (Kelly et al., 1983; Campisi et al., 1984) which suggests that c-myc may be an important signal for follicular cell growth.
Experimental evidence for a direct role of myc in follicular cell transformation is scanty, being limited to the finding that introduction of a myc expression vector was necessary to permit full transformation by an activated viral ras gene in an immortal rat thyroid line (Fusco et al., 1987) . There is no data on primary thyroid cells comparable to that for fibroblasts (Land et al., 1983) and Schwann cells (Ridley et al., 1988) .
While our genomic analysis does not entirely exclude structural changes (such as rearrangements with breakpoints lying outside the regions probed or small deletions/point mutations below the resolution of Southern blotting), failure to find amplification or rearrangement of c-myc, in agreement with previous studies (Terrier et al., 1988; Aasland et al., 1988) , argues against the involvement of any primary abnormality of this gene in thyroid tumours. Given the close correlation of myc amplification with loss of differentiation in several other human cancers, it was particularly important to exclude this possibility in anaplastic carcinoma of the thyroid, which was not adequately represented in earlier series.
Our findings for thyroid resemble observations on another human glandular epithelium, colon (Erisman et al., 1985; Sikora et al., 1987) , in which c-myc expression varies in relation to proliferative and/or differentiation state and is in general higher in tumours than normal tissue, again in the absence of any demonstrable abnormality of the c-myc locus.
We conclude therefore that, as in the colon (Calabretta et al., 1985) , increased c-myc expression in thyroid tumours most likely reflects the higher proportion of proliferating/less differentiated cells in tumour compared with normal epithelium, rather than any causal role in tumorigenesis per se.
Fos expression was also readily detectable in normal thyroid, at levels even higher than that of c-myc, but unlike myc was not increased in any thyroid tumour group. On the contrary, fos expression was reduced in one class of tumour, the follicular carcinomas, and moreover was undetectable in the only widely invasive case of FC in the series (which was also the least differentiated, as assessed both histologically and by thyroglobulin expression). These changes are very unlikely to be due to greater degradation of fos mRNA in these cases, since there was no corresponding fall in abundance of the equally unstable c-myc transcript, and these samples were not subject to any greater delay before freezing.
Although initial observation of a transient stimulation of fos expression by mitogens (even more marked than for c-myc) supported a role for fos in signalling proliferation (Kruijer et al., 1984) , induction of fos has since been observed in association with cessation of growth accompanying differentiation, e.g. induction of macrophage differentation in HL60 cells by phorbol esters (Mitchell et al., 1985) and of neuronal differentiation of PC12 cells by NGF (Morgan & Curran, 1986) . In the thyroid the only data available are observations on transient induction by TSH, analogous to that of other mitogens (Colletta et al., 1986) but since TSH mediates both proliferation and functional/ differentiation responses in thyrocytes, this does not distinguish between these two roles. Our finding of relatively high levels of fos expression in normal thyroid, analogous to similar findings in several other mitotically inactive cell types in vivo, notably macrophages (Wagner & Muller, 1986) , together with the loss of expression in the less differentiated tumours suggests a role in differentiation rather than growth in the follicular cell.
Since the start of this study, the product of the recently described oncogene c-jun has been shown to bind to, and act in concert with, fos protein in regulating gene transcription (Rauscher et al., 1988) . We have analysed a subset of the original series using a human c-jun probe (Ryseck et al., 1988) and find that the abundance of c-jun transcripts is closely similar to that offos and moreover declines in parallel with fos in the follicular carcinomas (data not shown).
As regards the other nuclear oncogenes, there was no reproducibly detectable expression of N-myc, L-myc, myb or p53 mRNA in either normal or tumour samples (although we cannot totally rule out small increases in tumours, since the detection limit of the techniques used is not known). Neither was there any evidence of genomic abnormalities on Southern analysis. These genes would appear therefore to be irrelevant to thyroid growth and neoplasia. This provides an interesting contrast with our recent study of tumours derived from the other epithelial cell type in the thyroid -the C cellwhich forms a tiny sub-population, distinct both embryologically and functionally from the follicular cell. C cell carcinomas showed a high incidence of N-myc expression which was undetectable in the normal C-cell (Boultwood et al., 1988) .
In conclusion it would appear from our data that there is little to support a direct role for this group of genes in thyroid follicular cell cancer. A major objective must now be to determine the additional genetic events which co-operate with ras oncogene activation to determine progression in these tumours. Both ourselves (unpublished data) and others (Aasland et al., 1988) have found no evidence for amplification of two other likely candidate genes: c-erbB and c-erbB2. We are currently exploring the possible role of anti-oncogenes in this regard.
